In consideration of our findings, this suggests that the therapeutic in vivo inhibition of LPA-LPA5 signaling would not only enhance CD8 T cell effector function but also provide the added benefit of lowering the threshold of TCR-mediated activation of naïve CD8 T cells recognizing low-affinity antigens typical of (non-mutated) tumor antigens. Here, CD8A is linked to neoplasm.